Application of repetitive transcranial magnetic stimulation combined with dapoxetine in treatment of primary premature ejaculation
By combining repetitive transcranial magnetic stimulation (rTMS) with dapoxetine, and utilizing frequency-dependent neural network remodeling, the problem of unstable efficacy of dapoxetine was solved, providing a safe and effective PPE treatment option that significantly improves ejaculatory control and quality of sexual life.
Patent Information
- Application Number
- CN202610371941.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-25
- Publication Date
- 2026-07-17
AI Technical Summary
The efficacy of existing dapoxetine treatment for primary premature ejaculation varies among individuals and is insufficient to meet the long-term management needs of PPE patients. Furthermore, there is a lack of clinical evidence for repetitive transcranial magnetic stimulation in the field of PPE, and there is a lack of effective combination therapy options.
Repetitive transcranial magnetic stimulation (rTMS) combined with dapoxetine was used to treat primary premature ejaculation. The frequency range of rTMS was 1~10Hz, and the target was located in the right primary motor cortex. Combined with drug therapy with dapoxetine, the neural network was remodeled through frequency-dependent electromagnetic-induced synaptic plasticity.
It significantly prolongs the intravaginal ejaculation latency (IELT), improves ejaculatory control and quality of sexual life, reduces anxiety and depressive symptoms, and provides a safe, reproducible, and innovative treatment pathway, enhancing the effectiveness and safety of treatment.
Smart Images
Figure CN122398768A_ABST